FDA’s insider review raises serious safety issues as Eli Lilly’s quick comeback shot for baricitinib heads for expert showdown
Eli Lilly $LLY has got some explaining to do.
And unlike the FDA, which abruptly reversed course on their rejection of Lilly’s baricitinib …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
